AlphAIAlphAI — Financial news for AI agents
investing.com$HIMS

Why is Hims & Hers Health stock sliding today?

Hims & Hers Health (HIMS) stock fell 3.7% in pre-market trading to $22.10 after missing Q3 2026 earnings estimates, reporting a loss of $0.14 per share vs. expected profit of $0.06. Revenue of $890.4M, up 49% YoY, missed estimates. Q4 guidance and full-year EBITDA outlook were cut. Gross margins fell to 57% from 74% due to a shift to lower-margin drugs and international expansion. Subscriber count also declined.

Original reporting
investing.com
Published Nov 10, 2026, 10:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$HIMS
Bearish
high confidence
Mentioned
$HIMS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HIMSBearishHigh
01

Why it matters

The earnings miss and guidance cut are primary catalysts for the stock's slide, suggesting further downside risk.

02

Market read

The article provides fresh earnings data that materially impacts HIMS valuation and may influence related telehealth stocks.

03

What to watch

International subscriber growth and upcoming peptide treatments may offset near‑term weakness.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Hims & Hers Health reported a Q3 loss, missed profit expectations, and cut Q4 revenue guidance, causing a pre‑open price decline.

Company-level read

Ticker impact

$HIMSBearishHigh confidence
Context

Q3 2026 earnings miss, loss of $0.14 per share and revenue guidance cut to $875M‑$895M triggered a 3.7% pre‑open slide.

Expected impact

likely further downside as investors price in weaker margins and lower outlook

Evidence & confidence

The surprise loss and guidance cut are fresh, material facts that directly affect valuation.

Market effects

Sector

Telehealth and digital health stocks may face broader scrutiny on margin pressures.

Regional

U.S. market sentiment dampened; no significant macro tailwind.

Global

Limited to HIMS and peers; no global macro effect.

Counterpoint

What could challenge this read

If the new GLP‑1 partnership with Eli Lilly drives future volume, the stock could rebound on long‑term upside.

Key entities

  • Company
    Hims & Hers Health

    Telehealth provider (ticker HIMS) reporting Q3 2026 results.

  • Partner
    Eli Lilly

    Partnered with HIMS on branded GLP‑1 weight‑loss drugs.

Read at source← All news

StoryHims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance

Also covered by

5 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com